PO.TB10.04 · 肿瘤生物学

解析浆细胞样尿路上皮癌的空间结构以指导治疗策略

Dissecting the spatial architecture of plasmacytoid urothelial carcinoma to inform therapeutic strategies

海报缩略图:解析浆细胞样尿路上皮癌的空间结构以指导治疗策略
编号 7436 展板 20 时间 4/22 09:00–12:00 区域 Section 28 主讲 Kathryn Gessner, MD;PhD
分会场 Microenvironmental Determinants of Therapy Response and Resistance 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kathryn H. Gessner, Jeffrey S. Damrauer, Siyao Liu, Mi Zhou, David Corcoran, Sara E. Wobker, William Kim

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

摘要 Abstract

中文摘要
浆细胞样尿路上皮癌(PUC)是膀胱癌的一种侵袭性组织学亚型,常与传统尿路上皮癌(CUC)共存。PUC 患者对以顺铂为基础的新辅助化疗反应较差,预后也比 CUC 患者差,凸显了治疗开发的重要性。阐明浆细胞样尿路上皮癌(PUC)的生物学特性可能揭示该变异体特有的治疗易感性。PUC 的定义是 E-cadherin 蛋白表达缺失,而来自其他癌症类型的证据提示 E-cadherin 信号、上皮-间质转化(EMT)、肿瘤微环境(TME)重塑与免疫检查点阻断反应性之间存在复杂关系。本研究旨在了解 E-cadherin 缺失对 PUC 中 TME 组成的影响以及细胞类型间的相互作用。我们获取了接受手术干预的尿路上皮癌患者的存档福尔马林固定石蜡包埋组织样本。进行了苏木精和伊红染色,并由一名泌尿生殖(GU)病理学家审阅,以识别符合传统或浆细胞样 UC 的组织学区域。E-cadherin 免疫组化确认了 PUC 组织学区域中 E-cadherin 的缺失。采用 10X Genomics Xenium In Situ 检测进行空间转录组学。使用 10X Genomics 人类多组织与癌症检测板和一个自定义 100 基因检测板的组合,原位检测了 477 个基因的表达,该自定义检测板旨在评估膀胱癌特异性基因的表达。Xenium 数据分析采用 10X Genomics Xenium Explorer 和基于 R 的软件包(包括 Seurat 和 HoodScanR)相结合的方式进行。分析聚焦于一个具有 PUC 和 CUC 组织学区域的混合组织学肿瘤。在 PUC 组织学区域内,CDH1(编码 E-cadherin 的基因)RNA 表达缺失,而与 EMT 信号相关的基因(Snail、vimentin)上调。表征了免疫细胞的相对比例,并识别了 PUC 特异性的细胞邻域。在 PUC 组织学区域,发现巨噬细胞浸润增加,且 PUC 与 CUC 区域之间鉴定出不同的巨噬细胞表型。本研究利用单细胞分辨率的空间转录组学,描绘了 PUC 结构,并展示了 E-cadherin 缺失、EMT 与巨噬细胞活化之间的相互作用。对 PUC 特异性表达和 TME 成分的进一步表征将有助于识别潜在的治疗易感性。
查看英文原文 English abstract
Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer that frequently co-exists with conventional urothelial carcinoma (CUC). Patients with PUC have worse response to cisplatin-based neoadjuvant chemotherapy and worse outcomes than patients with CUC, emphasizing the importance of therapeutic development. Elucidating the biology of plasmacytoid urothelial carcinoma (PUC) may reveal therapeutic vulnerabilities specific to this variant. PUC is defined by loss of E-cadherin protein expression, and evidence from other cancer types suggests a complex relationship between E-cadherin signaling, epithelial-to-mesenchymal transition (EMT), tumor microenvironment (TME) remodeling, and responsiveness to immune checkpoint blockade. This study seeks to understand the impact of E-cadherin loss on TME composition in PUC and the crosstalk between cell types. Archival formalin-fixed paraffin embedded tissue samples from patients with urothelial carcinoma who underwent surgical intervention was obtained. Hematoxylin and eosin stains were performed and reviewed by a GU pathologist to identify areas of histology consistent with conventional or plasmacytoid UC. Immunohistochemistry for E-cadherin confirmed loss of E-cadherin in histologic areas of PUC. The 10X Genomics Xenium In Situ assay was utilized to perform spatial transcriptomics. The expression of 477 genes was profiled in situ using a combination of the 10X Genomics Human Multi-Tissue and Cancer panel and a custom 100-gene panel, designed to evaluate the expression of bladder cancer specific genes. Xenium data analysis was performed using a combination of the 10X Genomics Xenium Explorer and R-based packages, including Seurat and HoodScanR. Analysis focused on a mixed histology tumor with histologic areas of PUC and CUC. Within areas of PUC histology, CDH1 (gene encoding E-cadherin) RNA expression was absent, and genes associated with EMT signaling (Snail, vimentin) were upregulated. Relative proportions of immune cells were characterized and PUC-specific cellular neighborhoods were identified. In the area of PUC histology, increased infiltration of macrophages was identified, with different macrophage phenotypes identified between PUC and CUC areas. Using spatial transcriptomics at single cell resolution, this study delineates PUC architecture and demonstrates the interplay between E-cadherin loss, EMT, and macrophage activation. Further characterization of PUC-specific expression and TME components will identify potential therapeutic vulnerabilities.
利益披露 Disclosure
K. H. Gessner, Revvity, Inc Other, Spouse employment. S. Liu, None.. M. Zhou, None.. D. Corcoran, None.. S. E. Wobker, None.

← 返回 AACR 2026 检索